Find Academic Supervisors

• Neuropathology
• Alzheimer's Disease
• Brain Tumors
• +7 more

Anita Huttner, MD is an Associate Professor of Pathology at Yale School of Medicine with extensive affiliations across Yale's research ecosystem. She holds primary appointments in the Department of Pathology and participates in numerous specialized research centers including the Alzheimer's Disease Research Center (ADRC), Brain Tumor Center, Genomics, Genetics, and Epigenetics Program, and Yale Cancer Center. Her dual expertise spans neuropathology and molecular diagnostic pathology, creating a unique interdisciplinary approach to understanding brain diseases. Dr. Huttner's research focuses on neurological disorders with particular emphasis on Alzheimer's disease, brain tumors, and epilepsy. She employs innovative techniques including subcellular proteomics, induced pluripotent stem cell (iPSC) modeling, and advanced imaging analysis to investigate disease mechanisms. Her work bridges traditional microscopic examination with modern genomic analysis, allowing her to incorporate genetic sequencing results into visual tumor analysis. Recent publications demonstrate her leadership in identifying biomarkers for neurological conditions and developing novel diagnostic approaches for brain disorders. Analysis of Dr. Huttner's recent publications (2023-2025) reveals a strong focus on Alzheimer's disease mechanisms, brain tumor classification using advanced imaging techniques, and neurological conditions like Tourette Disorder and epilepsy. Her work frequently employs cutting-edge methodologies including single-cell transcriptomics, subcellular proteomics, and AI-based analysis of medical imaging. These publications appear in high-impact journals such as Nature Neuroscience, Nature Aging, and Biological Psychiatry, demonstrating the significance of her contributions to the field. Averill A. Liebow Award for Excellence in the Teaching of Pathology Residents (2009) Nomination for the Alice Bohmfalk Teaching Award in Basic Science (2005) Dr. Huttner maintains an active research program with numerous collaborations across Yale and beyond. Her work involves both basic science investigations and clinical applications, with a particular focus on translating laboratory findings into improved diagnostic approaches and potential treatments. She serves as a Sub Investigator for the SV2A PET Imaging clinical trial focused on epilepsy patients, demonstrating her commitment to translational research that directly impacts patient care. Her mentorship extends to pathology residents, with recognition for excellence in teaching. Based at the Brady Memorial Laboratory at Yale, Dr. Huttner's work integrates multiple research approaches to understand brain pathology at both cellular and molecular levels. Her laboratory investigations focus on recreating brain disorders using stem cell technology to model conditions like epilepsy and Alzheimer's disease, with the ultimate goal of developing better treatments for neurological conditions and brain tumors.

• Immunology
• Virology
• Vaccine Development
• +5 more

Akiko Iwasaki is Sterling Professor of Immunobiology at Yale School of Medicine, with secondary appointments in Dermatology and Epidemiology of Microbial Diseases. She serves as Director of Yale's Center for Infection and Immunity and has been an HHMI Investigator since 2014. Her affiliations include joint roles with Yale Cancer Center, Center for RNA Science, and Women's Health Research at Yale. Her research focuses on: Mucosal immune defense mechanisms against viruses Long COVID pathophysiology and neuroimmune interactions Development of nasal vaccines to block viral transmission Virus-triggered autoimmunity and cancer pathogenesis Recent publications emphasize SARS-CoV-2 immunology, with trends showing strong focus on: Characterization of post-viral syndromes (Long COVID, ME/CFS) Mucosal vaccine efficacy and IgA response modulation Viral reservoir identification and therapeutic targeting Neuroimmune mechanisms in chronic disease Major scientific honors include: Keio Medical Science Prize (2025) TIME 100 Most Influential People (2024) National Academy of Sciences membership (2018) Else Kröner Fresenius Prize (2023) AAI Presidency (2023) She directs the Iwasaki Lab and Center for Infection and Immunity, coordinating multicenter studies like the Yale-Mount Sinai Long COVID initiative. As principal investigator of NIH-funded projects, she mentors graduate students and oversees translational research bridging virology and clinical immunology.

Nikhil JoshiView profile

Associate Professor

• Tumor Immunology
• Cancer Immunotherapy
• T cell biology
• +7 more

Nikhil Joshi, PhD is an Associate Professor with Tenure in the Department of Immunobiology at Yale School of Medicine. He serves as Co-leader of the Cancer Immunology Program at Yale Cancer Center and maintains affiliations with multiple Yale research initiatives including the Yale Center for Immuno-Oncology, Human and Translational Immunology Program, and Immunology Liver Center. His research focuses on understanding immune cell interactions with developing tumors, particularly investigating how T cell subtypes function in the tumor microenvironment using complex mouse models. The Joshi Lab combines advanced genetic modeling with immunologic techniques to address fundamental questions in tumor immunology. Analysis of recent publications (2022-2025) reveals a strong focus on T cell biology in cancer, with particular emphasis on T cell exhaustion mechanisms, immunoediting processes, tertiary lymphoid structures, and metabolic influences on tumor immunity. His work spans both basic immunological mechanisms and translational applications for cancer immunotherapy. Class of 1961 Cancer Research Award, Yale Cancer Center (2023) Basic Science Research Prize, Yale Cancer Center (2023) Young Investigators in Cancer Research, Pershing Square Sohn Prize (2022) Emerging Leader Award, Mark Foundation (2022) James B. Dougherty MD Award, Lung Cancer Research Foundation (2021) Professor Joshi maintains active research funding as evidenced by his substantial publication record in high-impact journals. His lab trains numerous students and postdocs, with frequent collaborators including Kelli Connolly, Gena Gora Foster, and Eric Fagerberg. The lab participates in multiple interdisciplinary initiatives at Yale, providing students with opportunities to work at the intersection of immunology, cancer biology, and computational approaches. The Joshi Laboratory focuses on engineering models to decode T-cell immunity in cancer, with research spanning tumor differentiation, T cell fate in cancer and health, and mechanisms of action for immune cells in tumor development and suppression.

• Gastrointestinal cancers
• Liver metastasis
• Pancreatic cancer biomarkers
• +12 more

Sajid A. Khan, MD is an Associate Professor of Surgery (Oncology) at Yale School of Medicine, Chief of Hepato-Pancreato-Biliary & Mixed Tumors, and Co-Director of Team Science at Yale Center for Clinical Investigation (YCCI). He serves as Co-Leader of the Advanced Hepatobiliary Disease Program at Yale Cancer Center. Dr. Khan is internationally recognized for superb clinical care and excellence in cancer research, with board certification in both Complex General Surgical Oncology and General Surgery. Yale School of Medicine - Associate Professor of Surgery (Oncology) Yale Cancer Center - Co-Leader, Advanced Hepatobiliary Disease Program Yale Center for Clinical Investigation (YCCI) - Co-Director of Team Science Hepatic Arterial Infusion (HAI) Program - Co-Director Southwest Oncology Group (SWOG) - Principal Investigator Dr. Khan earned his medical degree from SUNY Upstate Medical University in Syracuse, NY and completed his general surgery training at Oregon Health & Science University and Albert Einstein College of Medicine/Montefiore. He furthered his expertise with a research fellowship at Memorial Sloan-Kettering Cancer Center and a clinical and research fellowship at University of Chicago Medical Center. He is Board Certified in both Complex General Surgical Oncology and General Surgery. Dr. Khan's research program focuses on gastrointestinal cancers, utilizing modern molecular biology (metabolomics and transcriptomics) to improve understanding and treatment. His NIH-funded lab performs translational research exploring liver metastasis mechanisms, developing pancreatic cancer biomarkers, and identifying novel genomic cancer pathways. A distinctive aspect of his work examines how tumor metabolites and RNA expression relate to race/ethnicity and sex differences. His lab's research has resulted in over 100 publications in prestigious journals with more than 3,299 citations. Dr. Khan's clinical practice specializes in complex surgical oncology for tumors of the liver, pancreas, bile ducts, stomach, and colon, as well as melanoma and neuroendocrine tumors. He has performed over 1,800 oncologic surgeries at Yale Health System, incorporating a multidisciplinary team approach and minimally invasive techniques. His commitment to patient care extends beyond the operating room, emphasizing long-term relationships with patients and their families. Regional Top Doctor by Castle Connolly (2023, 2024, 2025) Membership Induction to Surgical Biology Club (2024) Medical Student Thesis Award (as Mentor) (2023) Consistently top percentile ranks for patient satisfaction Dr. Khan leads a federally funded research program with multiple NIH grants (R01s, R21s, KL2) and serves as Principal Investigator for a SWOG-sponsored national clinical trial on colorectal cancer chemoprevention. He chairs the Society of Surgery of the Alimentary Tract (SSAT) Research Committee and serves on editorial boards for Annals of Surgical Oncology, JAMA Oncology, and Indian Journal of Surgery. His leadership extends to multiple professional organizations including the Society of Surgical Oncology, American College of Surgeons, and American Society of Clinical Oncology. The Khan Lab conducts both wet and dry lab research, focusing on translational studies that bridge basic science discoveries with clinical applications. The lab's work on oligometastatic disease aims to identify which patients with limited metastases will benefit most from curative therapies. Located at 300 George Street, 6th Floor, the lab collaborates closely with other experts at the Yale Cancer Center to advance the field of gastrointestinal oncology.

Smita KrishnaswamyView profile

Associate Professor

• Unsupervised Machine Learning
• Manifold Learning
• Deep Learning
• +7 more

Smita Krishnaswamy is an Associate Professor of Genetics and Computer Science at Yale University with joint appointments in both departments. She is affiliated with multiple interdisciplinary programs including the Applied Mathematics Program, Computational Biology and Bioinformatics Program, Yale Center for Biomedical Data Science, Yale Cancer Center, and the Wu Tsai Institute. Her research bridges computational methods development with biomedical applications, focusing on unsupervised machine learning approaches for high-dimensional data analysis. Associate Professor of Genetics, Yale School of Medicine Associate Professor of Computer Science, Yale University Affiliated Faculty, Applied Mathematics Program Affiliated Faculty, Computational Biology and Bioinformatics Member, Yale Center for Biomedical Data Science Member, Yale Cancer Center Member, Wu Tsai Institute Dr. Krishnaswamy's research focuses on developing unsupervised machine learning techniques, particularly manifold learning and deep learning methods, to analyze high-dimensional biomedical data. Her lab creates algorithms for non-linear dimensionality reduction, data geometry learning, denoising, imputation, and inference of multi-granular structures from complex datasets. These methods are applied to diverse data types including single-cell RNA-sequencing, mass cytometry, electronic health records, and connectomic data across multiple biological systems. Her work spans several key application areas including immunology and immunotherapy, cancer research, neuroscience, developmental biology, and health outcomes analysis. The lab employs approaches from geometric deep learning, multiscale graph signal processing, and topological data analysis to extract meaningful biological insights from complex datasets. Recent publications demonstrate the lab's leadership in developing methods for spatial transcriptomics, brain-state trajectory modeling, and organ donation prediction. Excellence in Science Early-Career Investigator Award from FASEB (2022) Yale Cancer Center Class of '61 Cancer Research Award (2025) Dr. Krishnaswamy maintains active collaborations across Yale and secures research funding supporting her work in computational biomedicine. She advises students through multiple programs including Genetics, Computer Science, and the Biological and Biomedical Sciences Graduate Program, fostering interdisciplinary training at the intersection of computation and biomedicine. The Krishnaswamy Lab operates at the forefront of computational biomedicine, developing mathematical approaches that enable new biological discoveries from complex datasets.

• Proteomics
• Mass Spectrometry
• Protein Biochemistry
• +6 more

TuKiet Lam is a Research Scientist and Director of the Keck MS & Proteomics Resource at Yale School of Medicine's Department of Molecular Biophysics and Biochemistry. He holds joint leadership of the Discovery Proteomics Core of the Yale/NIDA Neuroproteomics Center and is affiliated with Yale Cancer Center's Cancer Signaling Networks Program. Dr. Lam's research focuses on advanced mass spectrometry applications in proteomics and metabolomics. Key areas include: Protein identification and quantitative profiling in complex biological systems Analysis of posttranslational modifications (phosphorylation, ubiquitination, palmitoylation) Biomarker discovery for neurological disorders and cancers Development of novel mass spectrometry workflows His work spans diverse samples including brain tissue, cerebrospinal fluid, extracellular vesicles, and clinical specimens. Recent publications demonstrate strong research output in neurodegeneration (Alzheimer's, Parkinson's), oncology (glioblastoma), and substance use disorders. Common themes include subcellular proteomics, extracellular vesicle characterization, and multi-omic approaches integrating proteomic data with transcriptomic and clinical findings. Dr. Lam leads the Keck MS & Proteomics Resource, which provides: High-resolution tandem mass spectrometry services Protein identification and quantification Posttranslational modification analysis Targeted metabolomics The facility supports numerous NIH-funded projects and is equipped with Orbitrap mass spectrometers maintained through NIH S10 grants.

• Urologic Oncology
• Prostate Cancer
• Health Services Research
• +3 more

Michael S. Leapman, MD, MHS is an Associate Professor of Urology at Yale School of Medicine with secondary appointment in Chronic Disease Epidemiology. He serves as Clinical Program Leader for the Prostate & Urologic Cancers Program at Yale Cancer Center and maintains a joint appointment at the West Haven VA Medical Center. Dr. Leapman specializes in urologic oncology with focus on prostate, bladder, kidney, and testicular cancers. Education includes: B.A. in Neurobiology & Behavior, Cornell University (2005) M.D., University of Maryland School of Medicine (2009) Residency in General Surgery & Urology, Mount Sinai Medical Center (2014) Fellowship in Urologic Oncology, University of California San Francisco (2016) M.H.S., Yale University (2022) His research program examines: Prostate cancer management strategies including active surveillance and robotic surgery Health services outcomes in urologic oncology Imaging stewardship and guideline-concordant care Healthcare disparities in diagnostic access Environmental sustainability in urologic practice He has pioneered work in single-port robotic prostatectomy and MRI-guided biopsy techniques. Honors and awards: John N. Forrest Jr. Prize for Mentorship (2022) Best Poster, European School of Oncology (2016) Conquer Cancer Foundation Merit Award (2015) First Place Essay, AUA Western Section (2015) Outstanding Abstract Award, UCSF (2015) Dr. Leapman participates in clinical trials including the SIMCAP trial for metastatic prostate cancer and serves as mentor through Yale's research training programs. His collaborative work appears in high-impact journals including Journal of the National Cancer Institute, European Urology, and JAMA Oncology.

• Epigenetics
• Germline Biology
• Transcriptional Regulation
• +5 more

Dr. Bluma Lesch is an Associate Professor at Yale School of Medicine with joint appointments in Genetics and Obstetrics, Gynecology & Reproductive Sciences. She directs a research program investigating epigenetic regulation in germline development and evolutionary biology, integrating molecular, computational, and developmental approaches. Her research focuses on: Epigenetic bivalency in germ cells Transgenerational inheritance mechanisms Chromatin dynamics in meiosis Evolution of gene regulatory networks Recent publications (2024-2025) demonstrate strong emphasis on: Histone modification mechanics Germline-specific chromatin remodeling Evolutionary transcriptomics Translational studies in fertility and disease models Honors include: Pew Biomedical Scholar (2021) Searle Scholar (2019) Burroughs Wellcome Career Award (2015) NIH Kirschstein Fellowship Hope Funds for Cancer Research Fellowship She leads the Lesch Lab , which employs genomic technologies and computational modeling to study epigenetic inheritance across biological scales.

• Genomics
• Bioinformatics
• Cancer Genetics
• +3 more

Dr. Francesc Lopez-Giraldez is a Research Scientist in the Department of Genetics at Yale School of Medicine, where he serves as Associate Director of Bioinformatics at the Yale Center for Genome Analysis (YCGA). He is also affiliated with the Genomics, Genetics, and Epigenetics Program at Yale Cancer Center and participates in the Yale-BI Biomedical Data Science Fellowship. Dr. Lopez-Giraldez received his BS in Biology from University of Girona (2000), MSc in Health and Life Sciences from Pompeu Fabra University (2004), and PhD in Evolutionary Genetics from Autonomous University of Barcelona (2006). He completed postdoctoral training through a Beatriu de Pinós fellowship from Generalitat de Catalunya (2009). His research spans genomics, bioinformatics, cancer genetics, and evolutionary genetics, with significant contributions to understanding congenital heart disease, immune checkpoint mechanisms, and mTOR signaling pathways. His work bridges computational biology with clinical applications, particularly in cancer genomics and developmental disorders. Dr. Lopez-Giraldez's publication record shows consistent productivity with numerous papers in high-impact journals including Nature, PNAS, and Journal of Investigative Dermatology. His research demonstrates expertise in genomic analysis, spatial transcriptomics, and molecular mechanisms underlying various diseases. National Cancer Institute Research Specialist Award (R50) (2023) Dr. Lopez-Giraldez has mentored students at various levels, including high school and graduate students. As Associate Director of Bioinformatics at YCGA, he oversees bioinformatics infrastructure and analysis pipelines that support numerous research projects across Yale. His NCI R50 award provides dedicated support for his specialized research contributions to cancer genomics. While specific lab details aren't provided in the text, his role as Associate Director of Bioinformatics at YCGA places him at the center of Yale's genomic research infrastructure, providing computational expertise and leadership for large-scale genomic studies across multiple disease areas.

• Autoimmune Diseases
• Tumor Biology
• Systemic Lupus Erythematosus
• +4 more

Dr. Mark Mamula is a Professor of Medicine in the Rheumatology Department at Yale School of Medicine, affiliated with Yale Cancer Center and its Cancer Immunology Program. He directs an active research laboratory investigating immune tolerance mechanisms in autoimmune diseases and cancer. His research focuses on: Posttranslational modifications of autoantigens in lupus and type 1 diabetes B-cell mediated antigen presentation and epitope spreading Development of anti-tumor vaccines for breast/colon cancer Oxidative tissue modifications in autoimmune pathology Biomarker discovery for β-cell stress in diabetes Recent publications (2021-2023) explore gene expression signatures in autoimmune diseases, protein modification mechanisms in lupus T-cell responses, and proteomic approaches to diabetes biomarkers. His work consistently bridges basic immunology with therapeutic applications. Dr. Mamula holds a PhD from the University of Oklahoma (1986), MS from Notre Dame (1982), and BA from UCLA (1979). He maintains active collaborations across immunology and rheumatology disciplines.

• Genetics
• Genomics
• DNA Sequence Analysis
• +2 more

Dr. Shrikant Mane is a Professor of Genetics at Yale School of Medicine, where he directs the Yale Center for Genome Analysis (YCGA) Shared Resource and The Keck Biotechnology Resource Laboratory. He has over 25 years of research experience in both academic and private industry settings, with expertise in genomic and proteomic analyses using microarray and high-throughput DNA sequencing technologies. Dr. Mane received his Ph.D. in Cancer Biology in 1985 and completed his postdoctoral training at Johns Hopkins University School of Medicine. He has published over 125 scientific articles and holds 2 patents. His research spans genetics, genomics, DNA sequence analysis, neuroscience, and cancer biology, with a particular focus on Mendelian genomics and disease gene discovery. His laboratory work has provided over 58,000 sequence analyses to 225 Yale and 124 non-Yale principal investigators from 72 national and 16 international institutions. Dr. Mane is one of four Principal Investigators of the Yale Center for Mendelian Genomics, established in 2012 through an $11.2 million grant from NHGRI. His recent publications (2023-2025) demonstrate a strong focus on identifying genetic causes of kidney disorders, congenital heart disease, and neurodevelopmental conditions through large-scale genomic studies published in high-impact journals including Nature, Nature Communications, and PNAS. Notable Achievements: Principal Investigator of the Yale Center for Mendelian Genomics ($11.2 million NHGRI grant) Director of Yale Center for Genome Analysis serving hundreds of researchers worldwide Published over 125 scientific articles in genetics and genomics Extensive experience with genomic technologies spanning 25+ years Dr. Mane's laboratory serves as a major resource for genomic analysis at Yale and beyond, supporting numerous research projects through cutting-edge sequencing and analysis capabilities. His research program bridges technological development with clinical applications, particularly in the area of Mendelian disease gene discovery.

• Biomedical Research
• Cystitis, Interstitial
• Drug Delivery Systems
• +7 more

Darryl T. Martin is an Assistant Professor in the Department of Urology at the Yale School of Medicine and a member of the Yale Cancer Center. His research focuses on understanding the biological factors and molecular determinants that drive cancer progression and metastasis, particularly in urologic cancers. Dr. Martin is affiliated with the Cancer Signaling Networks program and the Janeway Society at Yale, demonstrating his integration into multiple research communities within the institution. Dr. Martin received his PhD from Memorial University of Newfoundland, where he trained as a cancer molecular biologist studying tumor growth and differentiation under the supervision of Drs. Robert Gendron and Hélène Paradis. He then completed postdoctoral training with Dr. Robert M. Weiss at Yale University School of Medicine, focusing on drug delivery and cancer progression, which laid the foundation for his current research program. Dr. Martin's research program investigates three main areas: defining distant metastasis by elucidating biologic factors and molecular determinants; modulating the tumor microenvironment to transform immunosuppressive conditions into immune-activated states; and enhancing tumor targeting using surface-modified nanoparticles. His work combines molecular biology, translational science, and nanomedicine to develop novel approaches for cancer treatment, with particular emphasis on prostate and bladder cancers. Analysis of Dr. Martin's recent publication record reveals a strong translational focus, bridging basic molecular mechanisms with clinical applications. His work spans genomic testing for prostate cancer, treatment optimization for bladder cancer variants, and nanoparticle-based drug delivery systems, demonstrating both breadth and depth in urologic oncology research. Dr. Martin is an active member of several professional organizations: American Association for Cancer Research (AACR) Society for Basic Urologic Research (SBUR) American Society for Biochemistry and Molecular Biology (ASBMB) The Martin Lab is currently funded by Department of Defense (DoD) and foundation grants, supporting research on cancer progression and metastasis. Dr. Martin collaborates extensively with clinical colleagues at Yale, reflecting the interdisciplinary nature of modern cancer research and his commitment to translating laboratory discoveries into clinical applications. Dr. Martin's laboratory focuses on developing practical applications for cancer treatment, particularly through nanoparticle systems that can deliver drugs to malignant tissues with high specificity. His research represents an important bridge between basic cancer biology and clinical oncology, with potential to improve outcomes for patients with urologic malignancies.

• Prostate Cancer
• Cancer Therapy Resistance
• Molecular Mechanisms
• +7 more

Ping Mu is an Associate Professor with tenure in both the Department of Urology and Department of Pathology at Yale School of Medicine and a member of the Yale Cancer Center. His academic journey began with a BS in Biotechnology from Peking University (2007), followed by a PhD in Biomedical Sciences from Weill Medical College of Cornell University (2013), and postdoctoral training under Dr. Charles L. Sawyers at Memorial Sloan Kettering Cancer Center. In mid-2018, he established his independent laboratory at UT Southwestern as an assistant professor, where his research excellence led to rapid promotion to tenured associate professor before moving to Yale. Dr. Mu's research focuses on uncovering the molecular mechanisms driving resistance to targeted and immune therapies in prostate and other cancers. His lab pursues three exciting research directions: 1) Mechanisms of Therapy Resistance and Tumor Evolution, particularly lineage plasticity, epigenetic rewiring, and mutagenesis; 2) Tumor Microenvironment, Immune Modulation, and Spatial Heterogeneity; and 3) Translational Platforms: AI-Driven Precision Medicine and Patient-Derived Organoids. His work employs state-of-the-art techniques including 3D-cultured organoids, single-cell sequencing, and spatial transcriptomics. Dr. Mu's recent publications show a strong focus on lineage plasticity, epigenetic regulation, and therapy resistance mechanisms in prostate cancer. His high-impact work has been featured in top-tier journals including Science (2017), Cancer Cell (2020, 2023), Cancer Discovery (2024), Nature Cancer (2022), and Nature Genetics (2015), demonstrating a consistent trajectory of significant contributions to the field of cancer research. Selected Scientific Awards: NIH R37 MERIT Award (2021) NIH R01 Research Award (2024) AACR NextGen Stars Award (2020) Prostate Cancer Foundation Young Investigator Award Welch Foundation Research Award Dr. Mu maintains an active research program with multiple NIH and DoD-funded projects. His lab has pioneered important discoveries regarding lineage plasticity mechanisms and novel therapeutic approaches to overcome therapy resistance. The Mu Lab actively collaborates with other researchers at Yale Cancer Center and beyond, contributing to the vibrant research ecosystem at Yale. The lab is particularly known for its work with 3D-cultured organoids and spatial transcriptomics to model therapy resistance in prostate cancer.

• Hair follicle development
• Regeneration
• Dermal niche
• +7 more

Peggy Myung, MD, PhD is Vice Chair of Research and Associate Professor of Dermatology and Pathology at Yale School of Medicine. She maintains strong affiliations across multiple Yale entities including the Yale Cancer Center, Yale Stem Cell Center, Cancer Signaling Networks Program, and Pathology Research Program in Translational Biomedicine. Dr. Myung leads the Myung Lab which focuses on hair follicle development and regeneration research, with applications to understanding skin cancer mechanisms. Dr. Myung received her MD and PhD from the University of Pennsylvania in 2003, completed residencies at Hospital of the University of Pennsylvania and University Hospitals Case Medical Center, and a fellowship at Yale University School of Medicine in 2014. She is board certified in both Dermatology (2012) and Dermatopathology (2014, with recertification in 2025). Her research program investigates how heterotypic signals between the skin epidermis and dermis regulate robust and organized hair follicle growth during embryonic development and adult regeneration. The Myung Lab specifically examines: (1) how cellular behaviors such as cell divisions and movement are regulated by key morphogenetic signals during regeneration, (2) how these signals are spatially disseminated to ensure robust but patterned growth, and (3) how these mechanisms contribute to disorganized growth during tumorigenesis. The hair follicle serves as an ideal model for these studies due to its accessibility and well-characterized cyclical regeneration dependent on resident stem cells. Dr. Myung's recent publication record demonstrates consistent productivity in high-impact journals, with a growing emphasis on single-cell genomic techniques and computational approaches to understand cellular interactions at unprecedented resolution. Her work bridges developmental biology, dermatology, and cancer research, with particular focus on Wnt/β-catenin signaling and epithelial-mmesenchymal interactions. Dr. Myung has received notable recognition including: $30K Biotech Accelerator Award (June 2023) Yale Medicine 'Top Doctor' listing (2024) As Vice Chair of Research, Dr. Myung oversees research initiatives within the Department of Dermatology while maintaining an active laboratory program that combines multi-photon imaging, quantitative RNA fluorescent in situ hybridization, single-cell RNA/ATAC sequencing, and in vivo mouse genetic models. Her long-term goal is to develop novel treatments for hair loss and to prevent and treat non-melanoma skin cancer by applying knowledge of hair morphogenetic signals to suppress aberrant growth in carcinogenesis.

• Cancer Diagnostics
• Liquid Biopsy
• Circulating Tumor DNA
• +7 more

Abhijit Patel, MD, PhD, is an Associate Professor of Therapeutic Radiology at Yale School of Medicine and Medical Director of Lawrence & Memorial Cancer Care Center in Waterford. His research focuses on developing innovative liquid biopsy technologies for cancer detection and monitoring through analysis of circulating tumor DNA. Dr. Patel received his MD and PhD (Molecular Biophysics and Biochemistry) from Yale University, completed an internship at Memorial Sloan-Kettering Cancer Center, and pursued residency in radiation oncology at Harvard Medical School. His postdoctoral research was conducted at the Howard Hughes Medical Institute, Massachusetts General Hospital. His research program centers on developing ultrasensitive diagnostic tools to measure trace amounts of circulating tumor DNA molecules via analysis of genomic and epigenomic signatures. Key areas include early detection of new and recurrent cancers, assessment of treatment response, and tracking genomic changes in tumors over time. His work combines expertise from clinical oncology, molecular biology, chemistry, computer science, and microfluidics. Dr. Patel's publication record shows consistent output with multiple high-impact papers in journals like Nature Biomedical Engineering, Nucleic Acids Research, and JCO Precision Oncology. His recent work has focused on machine learning applications for predicting lymph node metastasis in lung cancer and technical innovations for analyzing ultra-short DNA fragments in liquid biopsies. His scientific contributions have been recognized with awards including the Lungevity Foundation Early Detection Award and Tina's Wish Foundation Research Award. Dr. Patel is actively involved in clinical trials related to cancer detection and treatment, particularly in lung cancer applications. As Medical Director at Lawrence & Memorial Cancer Care Center, he bridges laboratory research with clinical practice, ensuring his diagnostic innovations address real-world clinical needs. His work represents a promising approach to noninvasive cancer detection and monitoring that could significantly impact patient care.